Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. company information, Employees & Contact Information

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, Instagram, YouTube, and Facebook.
Looking for a particular Cellectar Biosciences, Inc. employee's phone or email?

Cellectar Biosciences, Inc. Questions

News

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million - Yahoo Finance

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million Yahoo Finance

$5.8M Raised: Cellectar Biosciences Secures Funding via Warrant Exercises to Advance CLR 121125 - Stock Titan

$5.8M Raised: Cellectar Biosciences Secures Funding via Warrant Exercises to Advance CLR 121125 Stock Titan

Cellectar Biosciences to Report Second Quarter Financial - GlobeNewswire

Cellectar Biosciences to Report Second Quarter Financial GlobeNewswire

Cellectar Biosciences, Inc. Announces Participation in Key Cancer Research Conferences and Panel Discussions This September - Quiver Quantitative

Cellectar Biosciences, Inc. Announces Participation in Key Cancer Research Conferences and Panel Discussions This September Quiver Quantitative

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research - Yahoo Finance

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research Yahoo Finance

Cellectar's Blood Cancer Drug Gets FDA Breakthrough Status, Eyes Accelerated Approval Path - Stock Titan

Cellectar's Blood Cancer Drug Gets FDA Breakthrough Status, Eyes Accelerated Approval Path Stock Titan

Breaking: Mayo Clinic to Lead Groundbreaking Triple-Negative Breast Cancer Trial for Cellectar's CLR 125 - Stock Titan

Breaking: Mayo Clinic to Lead Groundbreaking Triple-Negative Breast Cancer Trial for Cellectar's CLR 125 Stock Titan

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) - Yahoo Finance

Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) Yahoo Finance

Breakthrough Cancer Treatment Updates: Cellectar to Share Pediatric Brain Tumor Trial Data at Key September Events - Stock Titan

Breakthrough Cancer Treatment Updates: Cellectar to Share Pediatric Brain Tumor Trial Data at Key September Events Stock Titan

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit - Yahoo Finance

Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit Yahoo Finance

Cellectar Biosciences to Unveil Q2 2025 Financial Results and Key Corporate Updates Next Week - Stock Titan

Cellectar Biosciences to Unveil Q2 2025 Financial Results and Key Corporate Updates Next Week Stock Titan

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer - Yahoo Finance

Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer Yahoo Finance

Novel Pancreatic Cancer Radio-Conjugate: Cellectar to Present Breakthrough Treatment Data at AACR Conference - Stock Titan

Novel Pancreatic Cancer Radio-Conjugate: Cellectar to Present Breakthrough Treatment Data at AACR Conference Stock Titan

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research - Yahoo Finance

Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research Yahoo Finance

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules - Yahoo Finance

Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules Yahoo Finance

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) - Yahoo Finance

Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) Yahoo Finance

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - Yahoo Finance

Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split Yahoo Finance

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - Yahoo Finance

Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma Yahoo Finance

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) - Yahoo Finance

Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) Yahoo Finance

Nusano Signs Multi-Isotope Supply Agreement with Cellectar Biosciences to Fuel Cancer Drug Development - TechBuzz News

Nusano Signs Multi-Isotope Supply Agreement with Cellectar Biosciences to Fuel Cancer Drug Development TechBuzz News

Cancer Treatment Pipeline Advances: Cellectar Lands Game-Changing Deal for Rare Medical Isotopes - Stock Titan

Cancer Treatment Pipeline Advances: Cellectar Lands Game-Changing Deal for Rare Medical Isotopes Stock Titan

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire

Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update GlobeNewswire

Cellectar Biosciences, Inc. to Report 2024 Financial Results and Corporate Update on March 13, 2025 - Quiver Quantitative

Cellectar Biosciences, Inc. to Report 2024 Financial Results and Corporate Update on March 13, 2025 Quiver Quantitative

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 - The Manila Times

Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 The Manila Times

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewswire

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update GlobeNewswire

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer - Yahoo Finance

Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer Yahoo Finance

83.6% ORR — Cellectar's Iopofosine I‑131 Eligible to File with EMA for CMA, Aiming for EU Approval - Stock Titan

83.6% ORR — Cellectar's Iopofosine I‑131 Eligible to File with EMA for CMA, Aiming for EU Approval Stock Titan

8.6-Month Survival: Cellectar's Novel Radiotherapy Shows Promise in Incurable Pediatric Brain Cancer Trial - Stock Titan

8.6-Month Survival: Cellectar's Novel Radiotherapy Shows Promise in Incurable Pediatric Brain Cancer Trial Stock Titan

Cellectar Biosciences Announces Poster Presentation at AACR Conference on Preclinical Data for Novel Cancer Treatment CLR 121225 - Quiver Quantitative

Cellectar Biosciences Announces Poster Presentation at AACR Conference on Preclinical Data for Novel Cancer Treatment CLR 121225 Quiver Quantitative

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer - The Globe and Mail

Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer The Globe and Mail

Cellectar Biosciences: Tumor Inhibition in 3 Pancreatic Models | CLRB Stock News - Stock Titan

Cellectar Biosciences: Tumor Inhibition in 3 Pancreatic Models | CLRB Stock News Stock Titan

Cancer Drug Developer Cellectar Announces Major 1:30 Reverse Split, Shares Reduce to 1.8M - Stock Titan

Cancer Drug Developer Cellectar Announces Major 1:30 Reverse Split, Shares Reduce to 1.8M Stock Titan

Cancer Drug Developer Cellectar Raises Quick $2.5M Through Strategic Warrant Exercise - Stock Titan

Cancer Drug Developer Cellectar Raises Quick $2.5M Through Strategic Warrant Exercise Stock Titan

Cellectar Explores Sale Options: Promising Cancer Drug Pipeline Attracts Strategic Review - Stock Titan

Cellectar Explores Sale Options: Promising Cancer Drug Pipeline Attracts Strategic Review Stock Titan

FDA Breakthrough: New Cancer Drug Shows 83% Response Rate in Rare Blood Cancer Treatment - Stock Titan

FDA Breakthrough: New Cancer Drug Shows 83% Response Rate in Rare Blood Cancer Treatment Stock Titan

Breakthrough TNBC Treatment Advances: FDA to Review Novel Radiopharmaceutical Trial Protocol - Stock Titan

Breakthrough TNBC Treatment Advances: FDA to Review Novel Radiopharmaceutical Trial Protocol Stock Titan

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape - Yahoo Finance

Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape Yahoo Finance

Cellectar Biosciences: Still Working On That Hit (Maintain Buy) (NASDAQ:CLRB) - Seeking Alpha

Cellectar Biosciences: Still Working On That Hit (Maintain Buy) (NASDAQ:CLRB) Seeking Alpha

Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update - GlobeNewswire

Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update GlobeNewswire

Top Cellectar Biosciences, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant